Related Experiment Videos
Detecting recurrent bladder cancer: new methods and biomarkers.
1Department of Pathology and Laboratory Medicine, Albany Medical College, New Scotland Avenue, Albany, New York 12208, USA. rossj@mail.amc.edu
Expert Review of Molecular Diagnostics
|March 21, 2002
Summary
Microsatellite instability assays show the highest sensitivity and specificity for detecting recurrent bladder cancer compared to conventional urothelial cytology and other molecular tests. These advanced biomarkers offer improved cancer detection capabilities.
Area of Science:
- Urology
- Oncology
- Molecular Diagnostics
Background:
- Recurrent bladder cancer detection relies on conventional urothelial cytology.
- There is a need for more sensitive and specific diagnostic tools.
Purpose of the Study:
- To compare the efficacy of various biomarkers and molecular assays against conventional urothelial cytology for detecting recurrent bladder cancer.
Main Methods:
- Review and detailed consideration of multiple diagnostic tests.
- Included: BTA test, NMP 22 test, DNA ploidy, telomerase determinations, and microsatellite instability assays.
- Evaluation of additional biomarkers such as tumor antigens, growth factors, and molecular markers (e.g., p53 mutations).
Main Results:
- All evaluated molecular assays demonstrated some improvement over conventional cytology.
- Microsatellite instability assays exhibited the highest sensitivity and specificity among the tested methods.
- Various other biomarkers including cell cycle regulatory genes and p53 mutations were also considered.
Conclusions:
- Microsatellite instability assays represent a promising advancement for recurrent bladder cancer detection.
- Further research into these molecular markers may lead to improved diagnostic strategies.